Harnessing the power of nucleic acids to treat cancer

Exicure is pioneering the development of spherical nucleic acid technology as a promising avenue of therapeutic development to strengthen and prolong the body’s natural immune defenses against a wide range of cancers.

Go to the profile of Exicure
Sep 07, 2016
1
0
Page of
Go to the profile of Exicure

Exicure

Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene silencing drugs against validated targets. Its 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Its lead programs address diseases from inflammatory disorders to oncology.

No comments yet.